N Hassler1, S Gamsjaeger, B Hofstetter, W Brozek, K Klaushofer, E P Paschalis. 1. Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma CentreMeidling, 1st Medical Department, Hanusch Hospital, Heinrich Collin Str. 30, A-1140, Vienna, Austria.
Abstract
UNLABELLED: Raman microspectroscopic analysis of iliac crest from patients that were treated with alendronate (ALN) for 10 years revealed minimal, transient alterations in bone material properties confined to actively forming bone surfaces compared to patients that were on ALN for 5 years. These changes were not encountered in the bulk tissue. INTRODUCTION:Alendronate (ALN) and other bisphosphonates (BPs) are the most widely prescribed therapy for postmenopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, questions have been raised regarding potential detrimental effects that may be related to prolonged bone turnover reduction, although no definite cause-effect relationship has been established to date. The purpose of the present study was to evaluate bone material properties in patients that were receiving ALN for 5 or 10 years. METHODS: Raman microspectroscopic analysis was used to analyze iliac crest biopsies from postmenopausal women with osteoporosis who had been treated with ALN for 5 years and were then re-randomized to placebo (PBO, N = 14), 5 mg/day ALN (N = 10), or 10 mg/day ALN (N = 6) for another 5 years. The parameters monitored and expressed as a function of tissue age were (i) the mineral/matrix ratio (MM), (ii) the relative proteoglycan content (PG), (iii) the relative lipid content (LPD), (iv) the mineral maturity/crystallinity (MMC), and (v) the relative pyridinoline content (PYD). RESULTS: The obtained data indicate that 10-year ALN use results in minimal, transient bone tissue composition changes compared to use for 5 years, confined to actively forming trabecular surfaces, implying potential differences in bone matrix maturation that nevertheless did not result in differences of these values in bulk tissue. CONCLUSIONS: The data suggest that prolonged reduction in bone turnover during 10 years of therapy with ALN by itself is unlikely to be associated with adverse effects on bone material properties.
RCT Entities:
UNLABELLED: Raman microspectroscopic analysis of iliac crest from patients that were treated with alendronate (ALN) for 10 years revealed minimal, transient alterations in bone material properties confined to actively forming bone surfaces compared to patients that were on ALN for 5 years. These changes were not encountered in the bulk tissue. INTRODUCTION:Alendronate (ALN) and other bisphosphonates (BPs) are the most widely prescribed therapy for postmenopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, questions have been raised regarding potential detrimental effects that may be related to prolonged bone turnover reduction, although no definite cause-effect relationship has been established to date. The purpose of the present study was to evaluate bone material properties in patients that were receiving ALN for 5 or 10 years. METHODS: Raman microspectroscopic analysis was used to analyze iliac crest biopsies from postmenopausal women with osteoporosis who had been treated with ALN for 5 years and were then re-randomized to placebo (PBO, N = 14), 5 mg/day ALN (N = 10), or 10 mg/day ALN (N = 6) for another 5 years. The parameters monitored and expressed as a function of tissue age were (i) the mineral/matrix ratio (MM), (ii) the relative proteoglycan content (PG), (iii) the relative lipid content (LPD), (iv) the mineral maturity/crystallinity (MMC), and (v) the relative pyridinoline content (PYD). RESULTS: The obtained data indicate that 10-year ALN use results in minimal, transient bone tissue composition changes compared to use for 5 years, confined to actively forming trabecular surfaces, implying potential differences in bone matrix maturation that nevertheless did not result in differences of these values in bulk tissue. CONCLUSIONS: The data suggest that prolonged reduction in bone turnover during 10 years of therapy with ALN by itself is unlikely to be associated with adverse effects on bone material properties.
Authors: Birgit Hofstetter; Sonja Gamsjaeger; Roger J Phipps; Robert R Recker; Frank H Ebetino; Klaus Klaushofer; Eleftherios P Paschalis Journal: J Bone Miner Res Date: 2012-05 Impact factor: 6.741
Authors: S Gamsjaeger; B Hofstetter; E Zwettler; R Recker; J A Gasser; E F Eriksen; K Klaushofer; E P Paschalis Journal: Osteoporos Int Date: 2012-11-15 Impact factor: 4.507
Authors: Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte Journal: J Bone Miner Res Date: 2013-10-01 Impact factor: 6.741
Authors: Carmen Turbí; Gabriel Herrero-Beaumont; Juan Carlos Acebes; Antonio Torrijos; Jenaro Graña; Roberto Miguélez; JoséAntonio Sacristán; Fernando Marín Journal: Clin Ther Date: 2004-02 Impact factor: 3.393
Authors: E M Dennison; C Cooper; J A Kanis; O Bruyère; S Silverman; E McCloskey; B Abrahamsen; D Prieto-Alhambra; S Ferrari Journal: Osteoporos Int Date: 2019-06-07 Impact factor: 4.507
Authors: Gurjit S Mandair; Mohammed P Akhter; Francis W L Esmonde-White; Joan M Lappe; Susan P Bare; William R Lloyd; Jason P Long; Jessica Lopez; Kenneth M Kozloff; Robert R Recker; Michael D Morris Journal: Bone Date: 2021-04-14 Impact factor: 4.626
Authors: Maziar Shabestari; Erik Fink Eriksen; Eleftherios P Paschalis; Paul Roschger; Sonja Gamsjaeger; Klaus Klaushofer; Andrea Berzlanovich; Xavier Nogues; Lluis Puig; Adolfo Diez-Perez Journal: Bone Rep Date: 2017-03-02
Authors: M Schoeb; F Malgo; J J M Peeters; E M Winter; S E Papapoulos; N M Appelman-Dijkstra Journal: Osteoporos Int Date: 2020-04-08 Impact factor: 4.507
Authors: B M Misof; S Blouin; S Lueger; E P Paschalis; R R Recker; R Phipps; K Klaushofer; P Roschger Journal: J Musculoskelet Neuronal Interact Date: 2017-09-01 Impact factor: 2.041